I think we all agree that the ART-123 results in the published paper were not great. But the results from the phase-2b trial just starting could turn out better, so it’s premature, IMO, to write off ART-123 just yet. Regards, Dew
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.